Sabine Turri

Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial

Denis Soulières, Sandrine Faivre, Éva Remenár et al. · The Lancet Oncology · 2017 · 219 citations

Medicine, Oncology, Pharmacotherapy +11

Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE)

Sibylle Loibl, Lorena de la Peña, Valentina Nekljudova et al. · European Journal of Cancer · 2017 · 104 citations

Medicine, Oncology, Pharmacology +16

Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer

Christophe Massard, Kim Nguyen, Daniel Castellano et al. · European Journal of Cancer · 2017 · 91 citations

Pharmacy, Pharmacology, Pharmacotherapy +14

A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours.

Nicola Fazio, Roberto Buzzoni, Éric Baudin et al. · PubMed · 2016 · 86 citations · Full text

Medicine, Oncology, Pharmacology +15

Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non–Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial

Edward B. Garon, Shun Lü, Yasushi Goto et al. · Journal of Clinical Oncology · 2023 · 75 citations

Medicine, Oncology, Chemotherapy +15